Glioblastoma Market, An Area With High Trial Failure And Unmet Need Is Expected To Witness Significant Growth Owing To Increased Usage Of Bevacizumab, Temozolimide, Optune Gio Along With Emergence Of New Class Of Therapies | Delveinsight

(MENAFN- GlobeNewsWire - Nasdaq) The current therapeutic landscape of glioblastoma in the US is driven by the current treatment paradigm, which comprises therapies such as radiation, bevacizumab & its biosimilars, temozolimide as mono or combination therapies, Optune, along with several other systemic therapies. The glioblastoma market is estimated to change significantly during the period 2020–2034 owing to the expected launches of a few new classes such as vaccines and fusion proteins.

New York, USA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Glioblastoma Market, an Area With High Trial Failure And Unmet Need is Expected to Witness Significant Growth Owing to Increased Usage of Bevacizumab, Temozolimide, Optune Gio Along with Emergence of New Class of Therapies | DelveInsight

The current therapeutic landscape of glioblastoma in the US is driven by the current treatment paradigm, which comprises therapies such as radiation, bevacizumab & its biosimilars, temozolimide as mono or combination therapies, Optune, along with several other systemic therapies. The glioblastoma market is estimated to change significantly during the period 2020–2034 owing to the expected launches of a few new classes such as vaccines and fusion proteins.

DelveInsight's Glioblastoma Market Insights report includes a comprehensive understanding of current treatment practices, emerging glioblastoma drugs, market share of individual therapies, and current and forecasted glioblastoma market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Takeaways from the Glioblastoma Market Report

• According to DelveInsight's analysis, the market size of glioblastoma in the 7MM is expected to grow at a significant CAGR by 2034 owing to an increased usage of the current standard of care therapies along with the expected entry of a newer class of therapies
• Among the 7MM, the highest number of incident cases were observed in the US, which is around 14,500 in 2023.
• Targeted therapies for GBM often focus on molecular pathways like EGFR, mTOR, PI3K, and VEGF . AVASTIN (bevacizumab), a VEGF inhibitor, has five FDA-approved biosimilars, including MVASI, ZIRABEV, ALYMSYS, VEGZELMA (launched), and AVZIVI (approved December 2023).
• Drug development for brain cancer lags in comparison to other types of cancers with larger patient populations. Only 5% of new investigational drug applications submitted to the FDA for cancer therapies are successful , and for brain cancer, the rate of success has been closer to 1% over the past two decades.
• Prominent companies including Laminar Pharmaceuticals, BioMimetix, Enterome, Genenta Science, Medicenna Therapeutics, Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Biotherapeutics, MedImmune, DNAtrix, Imvax, MimiVax, CNS Pharmaceuticals, Oblato, Enterome, VBI Vaccines , and others, are actively working on innovative glioblastoma drugs.
• Even though trial failure rate is quite high in glioblastoma space and the probability of success remains quite uncertain, few novel glioblastoma therapies are still anticipated to enter the glioblastoma market during the forecast period, Some of the key glioblastoma treatments include LAM561, BMX-001, EO2401, Temferon, MDNA55, Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, MEDI4736 (durvalumab), DNX-2401, IGV-001, SurVaxM, Berubicin, OKN-007, EO2401, VBI-1901 , and others.
• Numerous cancer vaccines for the first, second, and above line of treatment are in the development phases. Northwest Biotherapeutics, TVAX Biomedical, Aivita Biomedical, Inovio Pharmaceuticals , and many others are developing cancer vaccines for GBM.
• Encouraging results have sparked hope for GBM immunotherapy, including checkpoint inhibitors, CAR T cells, oncolytic virotherapy, and vaccines , with ongoing studies exploring combinations to enhance efficacy and reduce side effects.

Discover which therapies are expected to grab the glioblastoma market share @ Glioblastoma Market Report

Glioblastoma Overview

Glioblastoma, also known as glioblastoma multiforme (GBM), is a highly aggressive and malignant brain tumor that originates from glial cells, which provide support and protection for neurons. The precise causes of glioblastoma remain largely unknown, though genetic mutations, environmental factors, and certain pre-existing conditions may contribute to its development. Common glioblastoma symptoms include persistent headaches, seizures, nausea, vomiting, cognitive changes, and motor deficits, which vary depending on the tumor's location within the brain.

Diagnosis typically involves neuroimaging techniques such as MRI or CT scans, which reveal the tumor's presence and its characteristics. A biopsy or surgical resection is often performed to obtain a tissue sample for histological analysis, confirming the diagnosis and guiding treatment strategies. Despite advances in treatment, glioblastoma remains challenging due to its aggressive nature and tendency to infiltrate surrounding brain tissue.

Glioblastoma Epidemiology Segmentation

The glioblastoma epidemiology section provides insights into the historical and current glioblastoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The glioblastoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Incident Cases of GBM
• Gender-specific Incident Cases of GBM
• Type-specific Incident Cases of GBM
• Incident Cases Based on Histologic Classification of GBM
• Incident Cases Based on the Primary Site of GBM
• Age-specific Incident Cases of GBM

Download the report to understand which factors are driving glioblastoma epidemiology trends @ Glioblastoma Epidemiological Insights

Glioblastoma Treatment Market

Treatment for glioblastoma multiforme typically involves a combination of surgery, chemotherapy, radiation therapy, or stereotactic radiosurgery. Surgery is a crucial component of the treatment but is rarely used alone. Given the rapid growth of glioblastomas, complete removal is often challenging. Thus, surgery aims for the maximum safe resection-removing as much of the tumor as possible while preserving brain function and healthy tissue.

After surgery, residual cancer cells are targeted with additional treatments like chemotherapy or radiation therapy. These subsequent treatments, known as adjuvant therapies, are applied once the diagnosis is confirmed. Due to the potential side effects of this comprehensive treatment approach, steroids are often prescribed to manage these side effects effectively.

The FDA has recognized that current treatments for GBM are only palliative, as recurrence is unavoidable following initial radiation. Additionally, chemotherapy is not effective, and there have been no comprehensive reports of objective responses. Despite advancements in patient survival with the introduction of TEMODAR (temozolomide) and AVASTIN (bevacizumab), there is still no effective cure for GBM, resulting in persistently low survival rates for those diagnosed with the condition.

Learn more about the market of glioblastoma @ Glioblastoma Treatment

Glioblastoma Emerging Drugs and Companies

Some of the drugs in the pipeline include BMX-001 (BioMimetix), EO2401 (Enterome), LAM561 (Laminar Pharmaceuticals), MDNA55 (Medicenna), Temferon (Genenta Science), and others. Other classes of emerging therapies include checkpoint inhibitors, CAR-T cells, oncolytic virotherapy, and vaccines, In fact, few Second and third-generation CAR-T cell therapies have also shown promising preclinical efficacy in extending patient survival in the treatment of GBM .

LAM561 (2-hydroxyoleic acid) is a synthetic form of oleic acid that can be taken orally and has the potential to cross the Blood Brain Barrier to reach brain cells. This drug modifies the plasma membrane composition in cancer cells, decreasing the activity of membrane-associated signaling proteins that contribute to tumor growth. Initial results for LAM561 in treating aggressive brain tumors, such as glioblastomas, are promising. Currently, it is undergoing a Phase II/III clinical trial. According to the company's development plan, LAM561 is expected to receive approval for treating glioma in adults by 2024, and for pediatric glioma by 2025/2026.

BMX-001 is a metalloporphyrin, a new type of small molecule with redox activity. It is designed to replicate the active site of superoxide dismutase and primarily works by modulating cellular signaling pathways. Currently, BMX-001 is undergoing a Phase II clinical trial for patients with newly diagnosed high-grade glioma.

In January 2020, BMX-001 received Orphan Drug Designation (ODD) , followed by a Fast Track Designation (FTD) in May 2020. In 2022, the FDA granted Breakthrough Therapy Designation (BTD) to BMX-001 for use alongside standard radiotherapy and temozolomide in treating newly diagnosed high-grade glioma.

The other pipeline therapies for glioblastoma include

• LAM561: Laminar Pharmaceuticals
• BMX-001: BioMimetix
• EO2401: Enterome
• Temferon: Genenta Science
• MDNA55: Medicenna Therapeutics
• Regorafenib: Bayer
• ONC201: Chimerix
• AV-GBM-1: Aivita Biomedical
• Enzastaurin (DB-102): Denovo Biopharma
• DCVax-L: Northwest Biotherapeutics
• MEDI4736 (durvalumab): MedImmune
• DNX-2401: DNAtrix
• IGV-001: Imvax
• SurVaxM: MimiVax
• Berubicin: CNS Pharmaceuticals
• OKN-007: Oblato
• EO2401: Enterome
• VBI-1901: VBI Vaccines

The anticipated launch of these emerging therapies are poised to transform the glioblastoma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the glioblastoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about glioblastoma clinical trials, visit @ Glioblastoma Treatment Drugs

Glioblastoma Market Dynamics

The glioblastoma market dynamics are anticipated to change in the coming years. Vaccine approaches, such as those developed by MimiVax (SurVaxM), Immunomic Therapeutics (ITI-1000), and IMVAX (IGV-001), offer an attractive adjuvant therapy for solid tumors by generating long-term immune surveillance against cancer cells. Nanocarrier delivery methods, including nanoparticles and prodrugs , are promising for drug transport across the blood-brain barrier.

Currently, the GBM market relies on temozolomide and bevacizumab , but lacks a curative strategy, presenting an opportunity for the development of new treatments. The conditional and time-limited approval of Daiichi's DELYTACT , an intratumoral oncolytic virus therapy, has paved the way for other companies like DNAtrix and Istari Oncology to explore oncolytic virus therapies as potential future treatments for brain cancer.

Furthermore, many potential therapies are being investigated for the treatment of glioblastoma, and it is safe to predict that the treatment space will significantly impact the glioblastoma market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the glioblastoma market in the 7MM.

However, several factors may impede the growth of the glioblastoma market. Almost all GBM tumors that respond to first-line therapy eventually recur, and there is no standard approach for successfully treating recurrent GBM. The clinical trial landscape for GBM is marked by long development times, inadequate dissemination of information, suboptimal decision-making, and low patient participation , necessitating larger multicenter studies.

The molecular and cellular complexity of gliomas, compounded by significant intertumoral and intratumoral heterogeneity, limits both diagnosis and treatment , impacting the development of effective biomarkers. Additionally, the brain's protective blood-brain barrier (BBB) prevents most new drugs from reaching brain tumors, posing a critical challenge in developing effective therapies for malignant brain tumors.

Moreover, glioblastoma treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the glioblastoma market growth may be offset by failures and discontinuation of emerging therapies , unaffordable pricing , market access and reimbursement issues , and a shortage of healthcare specialists . In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the glioblastoma market growth.

Glioblastoma Report Metrics	Details
Study Period	2020–2034
Glioblastoma Report Coverage	7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Glioblastoma Companies	Novocure, Roche, Merck, Bayer, Daiichi Sankyo, Novartis, Laminar Pharmaceuticals, BioMimetix, Enterome, Genenta Science, Medicenna Therapeutics, Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Biotherapeutics, MedImmune, DNAtrix, Imvax, MimiVax, CNS Pharmaceuticals, Oblato, Enterome, VBI Vaccines, and others
Key Glioblastoma products	Optune, AVASTIN, TEMODAR/TEMODAL, LAM561, BMX-001, EO2401, Temferon, MDNA55, Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, MEDI4736 (durvalumab), DNX-2401, IGV-001, SurVaxM, Berubicin, OKN-007, EO2401, VBI-1901, and others

Scope of the Glioblastoma Market Report

• Glioblastoma Therapeutic Assessment: Glioblastoma current marketed and emerging therapies
• Glioblastoma Market Dynamics: Conjoint Analysis of Emerging Glioblastoma Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Glioblastoma Market Access and Reimbursement

Discover more about glioblastoma drugs in development @ Glioblastoma Clinical Trials

Table of Contents

1	Key Insights
2	Report Introduction
3	Executive Summary
4	Key Events
5	Epidemiology and Market Forecast Methodology
6	GBM Market Overview at a Glance
6.1	Market Share (%) Distribution of GBM by Therapies in 2020
6.2	Market Share (%) Distribution of GBM by Therapies in 2034
7	Disease Background and Overview: GBM
7.1	Introduction
7.2	Classification of GBM
7.3	Glioblastoma Types
7.3.1	Astrocytomas
7.3.2	Ependymomas
7.3.3	Oligodendrogliomas
7.3.4	Mixed gliomas
7.3.5	Optic pathway gliomas
7.4	Symptoms
7.5	Causes
7.6	Pathophysiology
7.6.1	Macroscopic and Histological Features of GBM
7.6.2	Genetic and Molecular Pathogenesis
7.7	Inheritance of GBM
7.7.1	Genetic Variations of GBM
7.7.2	Isocitrate dehydrogenase mutations
7.7.3	O (6)-Methylguanine-DNA methyltransferase promoter methylation
7.7.4	Telomerase reverse transcriptase promoter mutations
7.7.5	Epidermal growth factor receptor aberrations
7.7.6	PTEN alterations
7.7.7	Other novel genetic aberrations
7.8	Molecular Classification
7.8.1	Specific Molecular Biomarkers
7.9	Diagnosis
8	Treatment and Management
8.1	Treatment Guidelines
8.1.1	NCCN Guidelines for Central Nervous System Cancers (Glioblastoma) (2024)
8.1.2	ESTRO-EANO Guideline on Target Delineation and Radiotherapy Details for Glioblastoma (2023)
8.1.3	Guidelines for the Management of Newly Diagnosed GBM (National Institute for Health and Care Excellence [NICE], 2021)
8.1.4	Clinical Recommendation for Glioblastoma (Associazione Italiana di Oncologia Medica [AIOM], 2021)
8.1.5	Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions (2020)
8.1.6	Guidelines for the Treatment of Adult GBM (Japanese Society of Neurological Surgery, 2019)
8.1.7	SEOM (Medical Oncology Spanish Society) Clinical Guidelines for Diagnosis and Treatment of GBM (2018)
9	Epidemiology and Patient Population
9.1	Key Findings
9.2	Assumptions and Rationale
9.3	Total Incident Cases of GBM in the 7MM
9.4	The US
9.4.1	Total Incident Cases of GBM in the US
9.4.2	Gender-specific Incident Cases of GBM in the US
9.4.3	Type-specific Incident Cases of GBM in the US
9.4.4	Incident Cases based on Primary Site of GBM in the US
9.4.5	Age-specific Incident Cases of GBM in the US
9.4.6	Incident Cases based on Histologic Classification of GBM in the US
9.4.7	Unmethylation of the MGMT Gene Promoter Cases in the US
9.4.8	BRAF V600E Mutation Cases in GBM in the US
9.4.9	Line-wise Treated Pool of GBM in the US
9.5	EU4 and the UK
9.5.1	Total Incident Cases of GBM in EU4 and the UK
9.5.2	Gender-specific Incident Cases of GBM in EU4 and the UK
9.5.3	Type-specific Incident Cases of GBM in EU4 and the UK
9.5.4	Incident Cases based on Primary Site of GBM in EU4 and the UK
9.5.5	Age-specific Incident Cases of GBM in EU4 and the UK
9.5.6	Incident Cases based on Histologic Classification of GBM in EU4 and the UK
9.5.7	Unmethylation of the MGMT Gene Promoter Cases in EU4 and the UK
9.5.8	BRAF V600E Mutation Cases in GBM in EU4 and the UK
9.5.9	Line-wise Treated Pool of GBM in EU4 and the UK
9.6	Japan
9.6.1	Total Incident Cases of GBM in Japan
9.6.2	Gender-specific Incident Cases of GBM in Japan
9.6.3	Type-specific Incident Cases of GBM in Japan
9.6.4	Incident Cases based on Primary Site of GBM in Japan
9.6.5	Age-specific Incident Cases of GBM in Japan
9.6.6	Incident Cases based on Histologic Classification of GBM in Japan
9.6.7	Unmethylation of the MGMT Gene Promoter Cases in Japan
9.6.8	BRAF V600E Mutation Cases in GBM in Japan
9.6.9	Line-wise Treated Pool of GBM in Japan
10	Patient Journey
11	Key Endpoints
12	Marketed Drugs
12.1	Key Competitors
12.2	AVASTIN (bevacizumab): Roche (Genentech)
12.2.1	Product Description
12.2.2	Regulatory Milestones
12.2.3	Other Developmental Activities
12.2.4	Safety and Efficacy
12.3	TEMODAR/TEMODAL (temozolomide): Merck
12.3.1	Product Description
12.3.2	Regulatory Milestones
12.3.3	Clinical Development
12.3.4	Safety and Efficacy
12.4	DELYTACT (teserpaturev/G47∆): Daiichi Sankyo
12.4.1	Product Description
12.4.2	Regulatory Milestones
12.4.3	Safety and Efficacy
12.5	TAFINLAR/FINLEE (dabrafenib) + MEKINIST (trametinib): Novartis
12.5.1	Product Description
12.5.2	Regulatory Milestones
12.5.3	Other Developmental Activities
12.5.4	Safety and Efficacy
12.6	OPTUNE GIO: Novocure
12.6.1	Product Description
12.6.2	Regulatory Milestones
12.6.3	Other Developmental Activities
12.6.4	Clinical Development
12.6.5	Safety and Efficacy
12.7	STIVARGA (regorafenib): Bayer
12.7.1	Product description
12.7.2	Regulatory Milestones
12.7.3	Other developmental activities
12.7.4	Clinical development
12.7.5	Safety and Efficacy
13	Emerging Drugs
13.1	Key Competitors
13.2	AV-GBM-1: Aivita Biomedical and TAE Life Sciences
13.2.1	Product Description
13.2.2	Other Developmental Activities
13.2.3	Clinical Development
13.2.4	Safety and Efficacy
13.3	DB107 (vocimagene amiretrorepvec-flucytosine): Denovo Biopharma
13.3.1	Product Description
13.3.2	Other Development Activities
13.3.3	Clinical Development
13.4	DCVax-L: Northwest Biotherapeutics and Advent BioServices
13.4.1	Product Description
13.4.2	Other Developmental Activities
13.4.3	Clinical Development
13.4.4	Safety and Efficacy
13.5	Eflornithine: Orbus Therapeutics
13.5.1	Product Description
13.5.2	Other Developmental Activities
13.5.3	Clinical Development
13.6	TVI-Brain-1: TVAX Biomedical
13.6.1	Product Description
13.6.2	Other Developmental Activities
13.6.3	Clinical Development
13.7	LAM561 (2-OHOA): Laminar Pharmaceuticals
13.7.1	Product Description
13.7.2	Other Developmental Activities
13.7.3	Clinical Development
13.7.4	Safety and Efficacy
13.8	VT1021: Vigeo Therapeutics
13.8.1	Product Description
13.8.2	Other Developmental Activities
13.8.3	Clinical Development
13.8.4	Safety and Efficacy
13.9	VERZENIO (abemaciclib, LY2835219): Eli Lilly and Company
13.9.1	Product Description
13.9.2	Other Development Activities
13.9.3	Clinical Development
13.9.4	Safety and Efficacy
13.10	PEMAZYRE (pemigatinib): Incyte Corporation
13.10.1	Product Description
13.10.2	Other Development Activities
13.10.3	Clinical Development
13.11	Paxalisib (GDC-0084): Kazia Therapeutics
13.11.1	Product Description
13.11.2	Other Developmental Activities
13.11.3	Clinical Development
13.11.4	Safety and Efficacy
13.12	BMX-001: BioMimetix
13.12.1	Product Description
13.12.2	Other Developmental Activities
13.12.3	Clinical Development
13.12.4	Safety and Efficacy
13.13	Bizaxofusp (MDNA55): Medicenna Therapeutics
13.13.1	Product Description
13.13.2	Other Developmental Activities
13.13.3	Clinical Development
13.13.4	Safety and Efficacy
13.14	ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
13.14.1	Product Description
13.14.2	Other Developmental Activities
13.14.3	Clinical Development
13.14.4	Safety and Efficacy
13.15	SurVaxM: MimiVax
13.15.1	Product Description
13.15.2	Other Developmental Activities
13.15.3	Clinical Development
13.15.4	Safety and Efficacy
13.16	OKN-007: Oblato
13.16.1	Product Description
13.16.2	Other developmental Activities
13.16.3	Clinical Development
13.16.4	Safety and efficacy
13.17	Berubicin: CNS Pharmaceuticals
13.17.1	Product Description
13.17.2	Other Developmental Activities
13.17.3	Clinical Development
13.17.4	Safety and Efficacy
13.18	IGV-001: Imvax
13.18.1	Product Description
13.18.2	Other Developmental Activities
13.18.3	Clinical Development
13.18.4	Safety and efficacy
13.19	BGB-290 (pamiparib): Beigene
13.19.1	Product Description
13.19.2	Clinical Development
13.19.3	Safety and Efficacy
13.20	EO2401: Enterome
13.20.1	Product Description
13.20.2	Other Developmental Activities
13.20.3	Clinical Development
13.20.4	Safety and Efficacy
13.21	VBI-1901: VBI Vaccines
13.21.1	Product Description
13.21.2	Other Developmental Activities
13.21.3	Clinical Development
13.21.4	Safety and Efficacy
13.22	Temferon: Genenta Science
13.22.1	Product Description
13.22.2	Other Development Activities
13.22.3	Clinical Development
13.22.4	Safety and Efficacy
13.23	NOX-A12 (olaptesed pegol): TME Pharma
13.23.1	Product Description
13.23.2	Other Developmental Activities
13.23.3	Clinical Development
13.23.4	Safety and Efficacy
13.24	INO-5401 + INO-9012 + LIBTAYO (cemiplimab): Inovio Pharmaceuticals and Regeneron Pharmaceuticals
13.24.1	Product Description
13.24.2	Other Developmental Activities
13.24.3	Clinical Development
13.24.4	Safety and Efficacy
13.25	Lerapolturev: Istari Oncology and FUJIFILM Diosynth Biotechnologies
13.25.1	Product Description
13.25.2	Other Developmental Activities
13.25.3	Clinical Development
13.25.4	Safety and Efficacy
13.26	Rhenium (186Re) obisbemeda: Plus Therapeutics
13.26.1	Product Description
13.26.2	Other Developmental Activities
13.26.3	Clinical Development
13.26.4	Safety and Efficacy
14	GBM: Seven Major Market Analysis
14.1	Key Findings
14.2	Market Outlook
14.3	Conjoint Analysis
14.4	Key Market Forecast Assumptions
14.5	Total Market Size of GBM in the 7MM
14.6	The US Market Size
14.6.1	Total Market Size of GBM in the US
14.6.2	Market Size of GBM by Therapies in the US
14.7	EU4 and the UK Market Size
14.7.1	Total Market Size of GBM in EU4 and the UK
14.7.2	Market Size of GBM by Therapies in EU4 and the UK
14.8	Japan Market Size
14.8.1	Total Market Size of GBM in Japan
14.8.2	Market Size of GBM by Therapies in Japan
15	Unmet Needs
16	SWOT Analysis
17	KOL Views
18	Market Access and Reimbursement
18.1	United States
18.1.1	Centre for Medicare and Medicaid Services (CMS)
18.2	EU4 and the UK
18.2.1	Germany
18.2.2	France
18.2.3	Italy
18.2.4	Spain
18.2.5	United Kingdom
18.3	Japan
18.3.1	MHLW
18.4	Market Access and Reimbursement of GBM
19	Appendix
19.1	Bibliography
19.2	Report Methodology
20	DelveInsight Capabilities
21	Disclaimer
22	About DelveInsight

Related Reports

Glioblastoma Epidemiology Forecast

Glioblastoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted glioblastoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Glioblastoma Pipeline

Glioblastoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glioblastoma companies, including Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies, among others.

Recurrent Glioblastoma Market

Recurrent Glioblastoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key recurrent glioblastoma companies including Accendatech USA Inc., Avance Clinical Pty Ltd, Genexine Inc., Biodexa Pharmaceuticals, PharmAbcine, Cordgenics LLC, Shanghai Simnova Biotechnology Co. Ltd, Novartis Pharmaceuticals, Cantex Pharmaceuticals, WPD Pharmaceuticals, AstraZeneca, Peregrine Pharmaceuticals, among others.

Recurrent Glioblastoma Pipeline

Recurrent Glioblastoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key recurrent glioblastoma companies, including Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., Chimerix, among others.

Recurrent Glioblastoma Epidemiology Forecast

Recurrent Glioblastoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted recurrent glioblastoma epidemiology in the 7MM, i.e., the United States, EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve .

Connect with us on LinkedIn | Facebook | Twitter

CONTACT: Contact Us Shruti Thakur ... +14699457679

MENAFN27012025004107003653ID1109134173